Waltham, MA-OXiGENE Inc. is launching a phase II clinical trial of its lead compound, Combretastatin A4 Prodrug (CA4P), in patients with myopic macular degeneration (MMD) under an investigational new drug application (NDA) submitted to the FDA.
Related Content:
Orbis in-person training taking flight once again
VIDEO: Eye trauma: Treatment trends and innovations
NYU Langone Health receives awards for quality, safety
